A: Semaglutide mimics GLP-1 to regulate appetite, reducing calorie intake and weight
Inside the cells, L-Carnitine transports fatty
The Wegovy pill works through semaglutide , a GLP-1 receptor agonist that mimics a hormone naturally produced in the gut
While some injectable versions may show higher average weight loss percentages in certain trials, the best medication is the one that you can consistently take and that fits your lifestyle and medical needs
Novo Nordisk filed the NDA with the FDA on December 18, 2025
References Lancet Diabetes Endocrinology (2024) Efficacy and safety of coadministered onceweekly cagrilintide 2.4 mg with Semaglutide 2.4 mg in type 2 diabetes: phase 2 trial Lancet (2021) Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant cagrilintide with Semaglutide 2.4 mg: phase 1b trial Lancet (2021) Onceweekly cagrilintide for weight management: dosefinding phase 2 trial in overweight/obesity StatPearls (2025) Semaglutide: pharmacology, indications, and clinical use overview Cureus (2024) Semaglutide: risks and benefits review (PMC) WHO (2010) Best practices for injection and related procedures (WHO toolkit) SigmaAldrich (2016) Peptide Handling Guide: storage, reconstitution, and stability LibreTexts (2020) Intradermal and subcutaneous injections: clinical procedures CDC (2024) Vaccine administration: subcutaneous injection technique Additional Research and Background These sources provide related context and are not presented as support for a specific statement above
